Barclays Maintains Overweight on Collegium Pharmaceutical, Lowers Price Target to $48

Benzinga Newsdesk www.benzinga.com Negative 90.0%

Neg 90% Neu 0% Pos 0%

Barclays analyst Glen Santangelo maintains Collegium Pharmaceutical (NASDAQ:COLL) with a Overweight and lowers the price target from $56 to $48.